Jeynes B J
Arch Pathol Lab Med. 1986 Dec;110(12):1143-8.
Atheroembolic lesions consist of both thrombus and atheroma, including cholesterol crystals; therefore, dissolution requires both a thrombotic agent and a lipid emulsifier. In vitro tests were performed in a Chandler tube apparatus to assess the effectiveness of predetermined dose and concentration levels for such agents. Between 0.065 and 0.1 mL of human atheroma, concentrated at 125 mg/mL, was added to 1 mL of recalcified rabbit whole blood in a Chandler tube to produce an atherothromboembolus. Specified amounts of streptokinase (SK) and/or taurochenodeoxycholate (TCDC) were introduced into the tube, either SK first, followed 30 minutes later by TCDC, or in the reverse order. The experimental thrombi were measured for length and weight, and samples from representative thrombi were processed and examined with both light and transmission electron microscopy. The combined SK/TCDC treatment appears to work best of all the treatments in reducing the size of the experimental thrombi and their cholesterol crystal components; and better than the TCDC/SK treatment. It is suggested that this combined treatment might be useful in the treatment of atherothromboembolism.
动脉粥样硬化栓塞性病变由血栓和动脉粥样硬化斑块组成，包括胆固醇结晶；因此，溶解需要一种血栓溶解剂和一种脂质乳化剂。在钱德勒管装置中进行体外试验，以评估此类药物预定剂量和浓度水平的有效性。将0.065至0.1 mL浓度为125 mg/mL的人动脉粥样硬化斑块加入到钱德勒管中的1 mL重新钙化的兔全血中，以产生动脉粥样硬化血栓栓子。将特定量的链激酶（SK）和/或牛磺鹅去氧胆酸盐（TCDC）引入管中，要么先加入SK，30分钟后再加入TCDC，要么顺序相反。测量实验性血栓的长度和重量，并对代表性血栓的样本进行处理，然后用光学显微镜和透射电子显微镜检查。在所有治疗方法中，SK/TCDC联合治疗在减小实验性血栓及其胆固醇结晶成分的大小方面似乎效果最佳；并且比TCDC/SK治疗效果更好。有人认为这种联合治疗可能对动脉粥样硬化血栓栓塞的治疗有用。
